NASDAQ:ESPR - Esperion Therapeutics Stock Price, Forecast & News

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Esperion Therapeutics Inc (NASDAQ:ESPR) released its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($2.37) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.95) by $0.42. The biopharmaceutical company had revenue of $0.98 million for the quarter, compared to the consensus estimate of $0.99 million. During the same period in the previous year, the business earned ($1.86) EPS. View Esperion Therapeutics' Earnings History.

Esperion Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Esperion Therapeutics.

12 analysts have issued 12-month price objectives for Esperion Therapeutics' shares. Their forecasts range from $45.00 to $191.00. On average, they anticipate Esperion Therapeutics' share price to reach $90.09 in the next twelve months. This suggests a possible upside of 49.0% from the stock's current price. View Analyst Price Targets for Esperion Therapeutics.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 6 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Esperion Therapeutics.

News headlines about ESPR stock have trended somewhat positive on Wednesday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Esperion Therapeutics earned a news impact score of 1.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an impact on the stock's share price in the next several days. View News Stories for Esperion Therapeutics.

Some companies that are related to Esperion Therapeutics include The Medicines (MDCO), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Horizon Therapeutics (HZNP), Amarin (AMRN), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY) and Mirati Therapeutics (MRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include Alon USA Partners (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), Ship Finance International (SFL), NVIDIA (NVDA), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), NXP Semiconductors (NXPI), Puma Biotechnology (PBYI) and Alibaba Group (BABA).

Esperion Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (4.03%), Credit Suisse AG (3.25%), Rhenman & Partners Asset Management AB (2.42%), Goldman Sachs Group Inc. (1.49%), Geode Capital Management LLC (1.27%) and Amundi Pioneer Asset Management Inc. (1.20%). Company insiders that own Esperion Therapeutics stock include Boxer Capital, Llc, Nicole Vitullo, Richard Bartram, Roger S Newton, Target N V Biotech and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.

ESPR stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., State Street Corp, Credit Suisse AG, Rafferty Asset Management LLC, Spark Investment Management LLC, Oxford Asset Management LLP, Alliancebernstein L.P. and Charles Schwab Investment Management Inc.. Company insiders that have sold Esperion Therapeutics company stock in the last year include Nicole Vitullo, Richard Bartram and Roger S Newton. View Insider Buying and Selling for Esperion Therapeutics.

ESPR stock was bought by a variety of institutional investors in the last quarter, including Rothschild & Co. Asset Management US Inc., Candriam Luxembourg S.C.A., Moody Aldrich Partners LLC, Goldman Sachs Group Inc., AXA, Sei Investments Co., Man Group plc and Pinnacle Associates Ltd.. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech and Timothy M Mayleben. View Insider Buying and Selling for Esperion Therapeutics.

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ESPR stock can currently be purchased for approximately $60.45.

Esperion Therapeutics has a market capitalization of $1.65 billion. The biopharmaceutical company earns $-201,810,000.00 in net income (profit) each year or ($7.54) on an earnings per share basis. Esperion Therapeutics employs 76 workers across the globe.View Additional Information About Esperion Therapeutics.

The official website for Esperion Therapeutics is http://www.esperion.com/.

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]